The field of cardio-oncology, also referred to as onco-cardiology, has grown over time to address the ever-increasing cardiovascular issues of patients with cancer and survivors. Anthracyclines, especially doxorubicin, are well known in this field, due to its popularity to treat various types of oncohematological diseases in children and adults. Much of the focus of cardio-oncology has been on adults. Although children represent around 5% of new cancer diagnoses each year in the United States, the high 5-year survival rate (>85%) in this age group equates to nearly half million survivors of pediatric cancer with decades of life expectancy after cancer treatment, being part of a growing and aging population at risk for therapy-related cardiovascular disease (Bell, Clayton. Am J Physiol Heart Circulat Physiol. https://doi.org/10.1152/ajpheart.00338.2025 , 2025).